An Overview of Axon Enterprise Stock Performance

A strong performer from today's afternoon trading session is Axon Enterprise, whose shares rose 5.2% to $380.57 per share. For those of you thinking about investing in the stock, here is a brief value analysis of the stock using the company's basic fundamental ratios.

Axon Enterprise's Valuation Is in Line With Its Sector Averages:

Axon Enterprise, Inc. develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. The company belongs to the Industrials sector, which has an average price to earnings (P/E) ratio of 25.19 and an average price to book (P/B) ratio of 3.17. In contrast, Axon Enterprise has a trailing 12 month P/E ratio of 100.2 and a P/B ratio of 14.91.

Axon Enterprise's PEG ratio is 3.71, which shows that the stock is probably overvalued in terms of its estimated growth. For reference, a PEG ratio near or below 1 is a potential signal that a company is undervalued.

Exceptional EPS Growth but Declining Revenues:

2018 2019 2020 2021 2022 2023
Revenue (M) $420 $531 $681 $863 $1,190 $343
Operating Margins 6% -1% -2% -19% 8% 45%
Net Margins 7% 0% 0% -7% 12% 51%
Net Income (M) $29 $1 -$2 -$60 $147 $174
Net Interest Expense (M) $3 $8 $8 $1 $4 $42
Depreciation & Amort. (M) $11 $11 $12 $16 $20 $28
Diluted Shares (M) 58 60 62 66 73 75
Earnings Per Share $0.5 $0.01 -$0.03 -$0.91 $2.03 $2.31
EPS Growth n/a -98.0% -400.0% -2933.33% 323.08% 13.79%
Avg. Price $51.33 $60.8 $89.5 $163.31 $120.44 $382.21
P/E Ratio 98.71 6080.0 -2983.33 -179.46 58.18 162.64
Free Cash Flow (M) $53 $50 -$34 $75 $180 $130
CAPEX (M) $11 $16 $73 $50 $56 $60
Current Ratio 3.36 3.12 3.83 2.65 3.0 3.0

Axon Enterprise has strong operating margins with a positive growth rate and exceptional EPS growth. Additionally, the company's financial statements display an excellent current ratio of 3.0 and positive cash flows. Furthermore, Axon Enterprise has declining revenues and increasing reinvestment in the business.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS